RxDoctor Payments Data

Elisa Krill-Jackson, MD

Hematology & Oncology · Miami, FLNPI 1427046085

Payments from drug & device makers

$604,020in general payments, 2019–2025

Across 675 payments — averaging $894.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$179K
  • Veru Inc.$159K
  • Eli Lilly$98K
  • Pfizer$93K
  • Lilly USA, LLC$42K
  • Genentech, Inc.$7K
  • plus $27K from 51 others
$2,261in research payments, 2019–2025

Across 2 payments — averaging $1130.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Consulting fees$15,20621%
  • Speaking & faculty fees$40,37556%
  • Grants$2500%
  • Travel & lodging$5,0937%
  • Food & beverage$10,86015%
  • Education$2120%
  • Other$2990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$604,020 in reported general payments places this provider in the 80th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$72,899
Medicare patients
343
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib31$487,601
VerzenioAbemaciclib30$447,747
TruqapCapivasertib17$359,404
ImbruvicaIbrutinib15$258,618
KisqaliRibociclib Succinate12$208,222
Everolimus16$29,949
Exemestane65$10,489
Letrozole121$3,365
Anastrozole94$1,998
Tamoxifen Citrate42$1,002
Hydroxyurea12$636
Dexamethasone32$517
Duloxetine Hcl19$273
Nystatin17$214
Temazepam12$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$93,141$487,60131 claims
Lilly USA, LLCVerzenio$41,588$447,74730 claims
AstraZenecaTruqap$1,642$359,40417 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$14$258,61815 claims
NovartisKisqali$6,230$208,22212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →